GSK2636771 clinical trials
Also written GSK2636771.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses GSK2636771 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 5
National Cancer Institute (NCI) (3) · GlaxoSmithKline (2) · M.D. Anderson Cancer Center (1) · Yonsei University (1)
Often tested with
Tested in the same studies.
Adavosertib (1) · Afatinib (1) · Binimetinib (1) · Capivasertib (1) · Copanlisib (1) · Copanlisib hydrochloride (1) · Crizotinib (1) · Dabrafenib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses GSK2636771 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439188Written as PI3K-beta Inhibitor GSK2636771
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as PI3K-beta Inhibitor GSK2636771
- Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03131908Written as GSK2636771
- Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439149Written as PI3K-beta Inhibitor GSK2636771
- PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric AdenocarcinomaCompletedPhase 1/2Yonsei UniversityNCT02615730Written as GSK2636771
- Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate CancerCompletedPhase 1GlaxoSmithKlineNCT02215096Written as GSK2636771
- A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) DeficiencyCompletedPhase 1GlaxoSmithKlineNCT01458067Written as GSK2636771
Codes
What other systems call GSK2636771 · ClinicalTrials.gg INT000955
- MeSH (NLM) C000627739GSK2636771Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) DW94IAT0LSGSK-2636771Confirmed FDA, NLM
- NCI Thesaurus C106261PI3K-beta Inhibitor GSK2636771One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627739 | GSK2636771 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DW94IAT0LS | GSK-2636771 | Confirmed FDA, NLM |
| NCI Thesaurus | C106261 | PI3K-beta Inhibitor GSK2636771 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.